Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Keytruda resistance shown as a monotherapy in anal cancer

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 25, 2024 10:24pm

111 Views

Post# 35952112

RE:RE:RE:RE:Keytruda resistance shown as a monotherapy in anal cancer

Merck (MSD) is now looking to combine other I/O agents with Keytruda to enhance the immune checkpoint inhibitors effectiveness. ONCY's pelareorep is demonstrating that it fits Merck's need.

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?